N-acetylcysteine (NAC) for the Treatment of Acute Exacerbation of COPD

PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 18, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

N-acetylcysteine

Patients will be randomized to receive oral N-acetylcysteine at 600 mg twice daily for 1 week. The randomization will be done via computer software with half of the patients randomized to receive NAC. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.

DRUG

Placebo

Patients will be randomized to receive placebo for 1 week. The randomization will be done via computer software with half receive placebo. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.

Trial Locations (1)

Unknown

RECRUITING

Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

Queen Mary Hospital, Hong Kong

OTHER